Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifabutin

FDA-approved product (capsule, oral), marketed as Mycobutin, Rifabutin.

Registered studies
50+
Lab records
15
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifabutin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Mycobacterium avium complex disease
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB04; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifabutin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA84.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli64.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 15 of 15 lab records
Open Rifabutin in ChEMBL Registered studies below
Show the 15 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifabutin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra

    NCT01259219 · start 2010-11

    Registered record
    Registry ID
    NCT01259219
    Conditions
    Children With Confirmed HIV Infection; Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose; Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
    Interventions
    Mycobutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2010-11
    Completion
    2012-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren With Confirmed HIV Infection; Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose; Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
    InterventionMycobutin
    PhasePhase 1
    Registry statusUnknown

  • Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)

    NCT00925535 · start 2010-05

    Registered record
    Registry ID
    NCT00925535
    Conditions
    Healthy Volunteers
    Interventions
    Lersivirine; Rifabutin; Lersivirine; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05
    Completion
    2010-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLersivirine; Rifabutin; Lersivirine; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

    NCT00869518 · start 2009-07

    Registered record
    Registry ID
    NCT00869518
    Conditions
    Staphylococcus Aureus; HIV Infections
    Interventions
    rifabutin plus trimethoprim sulfamethoxazole; placebo plus trimethoprim-sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-07
    Completion
    2010-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; HIV Infections
    Interventionrifabutin plus trimethoprim sulfamethoxazole; placebo plus trimethoprim-sulfamethoxazole
    PhasePhase 2
    Registry statusTerminated

  • Safety And Efficacy Of Rifabutin In HIV Patients

    NCT00810446 · start 2009-06

    Registered record
    Registry ID
    NCT00810446
    Conditions
    Non-tuberculous Mycobacterial Diseases; Tuberculosis; Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
    Interventions
    rifabutin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2018-03
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-tuberculous Mycobacterial Diseases; Tuberculosis; Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
    Interventionrifabutin
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa

    NCT00640887 · start 2009-02

    Registered record
    Registry ID
    NCT00640887
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    rifabutin in combination with efavirenz; rifabutin in combination with nevirapine; rifabutin in combination with lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-10
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    Interventionrifabutin in combination with efavirenz; rifabutin in combination with nevirapine; rifabutin in combination with lopinavir/ritonavir
    PhasePhase 2
    Registry statusCompleted

  • Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

    NCT00810407 · start 2008-11

    Registered record
    Registry ID
    NCT00810407
    Conditions
    Tuberculosis; Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
    Interventions
    rifabutin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-11
    Completion
    2016-07
    Enrolment
    628

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
    Interventionrifabutin
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis

    NCT00513552 · start 2007-07

    Registered record
    Registry ID
    NCT00513552
    Conditions
    Crohn's Disease
    Interventions
    Rifabutin, Clarithromycin, and Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-07
    Completion
    2007-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionRifabutin, Clarithromycin, and Clofazimine
    PhasePhase 4
    Registry statusWithdrawn

  • TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

    NCT00023413 · start 1999-11

    Registered record
    Registry ID
    NCT00023413
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Rifabutin; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-11
    Completion
    2004-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionRifabutin; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

    NCT00023361 · start 1999-02

    Registered record
    Registry ID
    NCT00023361
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-02
    Completion
    2003-02
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionRifabutin
    PhaseNot applicable
    Registry statusCompleted

  • Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients

    NCT02184078 · start 1998-10

    Registered record
    Registry ID
    NCT02184078
    Conditions
    HIV Infections
    Interventions
    Nevirapine; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-10
    Completion
    Not recorded
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine; Rifabutin
    PhasePhase 4
    Registry statusCompleted

  • Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

    NCT00598962 · start 1994-12

    Registered record
    Registry ID
    NCT00598962
    Conditions
    Mycobacterium Avium Complex
    Interventions
    Azithromycin; Rifabutin/rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1994-12
    Completion
    2017-05-18
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium Complex
    InterventionAzithromycin; Rifabutin/rifampin
    PhasePhase 4
    Registry statusCompleted

  • Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

    NCT00000877

    Registered record
    Registry ID
    NCT00000877
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-10
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

    NCT00001030

    Registered record
    Registry ID
    NCT00001030
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Clarithromycin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-06
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionClarithromycin; Rifabutin
    PhasePhase 3
    Registry statusCompleted

  • A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

    NCT00001995

    Registered record
    Registry ID
    NCT00001995
    Conditions
    Mycobacterium Avium-Intracellulare Infection; HIV Infections
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-Intracellulare Infection; HIV Infections
    InterventionRifabutin
    PhaseNot applicable
    Registry statusCompleted

  • Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

    NCT00002032

    Registered record
    Registry ID
    NCT00002032
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionRifabutin
    PhaseNot applicable
    Registry statusCompleted